Moreover, p16 expression and the proliferation rate were suggested as relevant markers of the metastatic potential of melanomas, thus highlighting the potential value of p16 immunophenotype evaluation for the treatment plan of cutaneous malignant melanocytic lesions [19]. The gene discussed is CDKN2A; the disease is melanoma.